VERAXA Biotech AG (NASDAQ: VRXA) announced that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone under its collaboration with OmniAb (NASDAQ: OABI). OmniAb has successfully completed its discovery work, allowing the program to advance into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
The collaboration, launched in May 2025, leverages OmniAb’s antibody discovery technologies, including its OmniClic platform, while VERAXA applies its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
This advancement is significant for the biopharmaceutical industry, particularly in the field of oncology. Bispecific ADCs represent a next-generation approach that could enhance tumor specificity and reduce off-target effects compared to traditional ADCs. By targeting two distinct tumor antigens, VXA-222 may improve therapeutic index and efficacy against heterogeneous solid tumors. For business leaders, this development underscores the growing trend of strategic partnerships in biotech, where companies combine complementary technologies to accelerate innovation. The collaboration between VERAXA and OmniAb exemplifies how specialized platforms can be integrated to create novel therapeutics.
The milestone also highlights the progress in antibody engineering and conjugation technologies. VERAXA’s proprietary linker technology is crucial for stable attachment of cytotoxic drugs to antibodies, while OmniAb’s platform enables rapid generation of high-affinity antibodies. The successful completion of discovery work suggests that the program is on track for preclinical development, potentially leading to clinical trials in the coming years.
For investors, this news may signal confidence in VERAXA’s pipeline and its ability to execute on complex drug development programs. The company’s focus on bispecific T cell engagers and ADCs positions it in competitive but high-potential areas of immuno-oncology. The exclusive rights to develop and commercialize products from the collaboration provide a clear path to market, subject to regulatory success.
More information about the collaboration and VERAXA’s pipeline can be found in the company’s newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/qMRuJ.
